calendar
153 catalysts · 3,728 phase readout · 2,104 8k filing · 276 earnings · 172 phase 2 completion · 152 grant · 133 drug shortage
next 91 dayslessmore
MonWedFri
153 catalysts · 3,728 phase readout · 2,104 8k filing · 276 earnings · 172 phase 2 completion · 152 grant · 133 drug shortage
Supplement type: Normal 180 Day Track No User Fee. Product code: MJO. Advisory committee: OR. Decision: APPR
Supplement type: 30-Day Notice. Product code: MDP. Advisory committee: GU. Decision: OK30
Supplement type: 30-Day Notice. Product code: QZK. Advisory committee: CV. Decision: OK30
Supplement type: 30-Day Notice. Product code: LWR. Advisory committee: CV. Decision: OK30
Supplement type: 30-Day Notice. Product code: MFE. Advisory committee: NE. Decision: OK30
Supplement type: 30-Day Notice. Product code: MCM. Advisory committee: EN. Decision: OK30
Supplement type: 30-Day Notice. Product code: NZK. Advisory committee: NE. Decision: OK30
Supplement type: 30-Day Notice. Product code: LPM. Advisory committee: OP. Decision: OK30
Supplement type: 30-Day Notice. Product code: MOZ. Advisory committee: OR. Decision: OK30
Supplement type: 135 Review Track For 30-Day Notice. Product code: NPV. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: NPT. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: NPV. Advisory committee: CV. Decision: APPR
Supplement type: 30-Day Notice. Product code: MCX. Advisory committee: CV. Decision: OK30
Supplement type: 30-Day Notice. Product code: OAD. Advisory committee: CV. Decision: OK30
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Normal 180 Day Track No User Fee. Product code: MWG. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: QZH. Advisory committee: TX. Decision: APPR
Supplement type: Real-Time Process. Product code: NIK. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Normal 180 Day Track No User Fee. Product code: NAW. Advisory committee: RA. Decision: APPR
Supplement type: 30-Day Notice. Product code: MRA. Advisory committee: OR. Decision: OK30
Supplement type: 30-Day Notice. Product code: QPY. Advisory committee: PM. Decision: OK30
Supplement type: Real-Time Process. Product code: LWP. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: NVN. Advisory committee: CV. Decision: APPR
Supplement type: Normal 180 Day Track. Product code: DSQ. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Special (Immediate Track). Product code: NPW. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: NVN. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: QFV. Advisory committee: CV. Decision: APPR
Supplement type: Special (Immediate Track). Product code: QQK. Advisory committee: GU. Decision: APPR
Supplement type: 30-Day Notice. Product code: NJL. Advisory committee: OR. Decision: OK30
Therapy area: Undisclosed. Indication: Unspecified
Therapy area: Dermatology. Indication: Chronic Urticaria
Therapy area: Oncology. Indication: Solid Tumor
Therapy area: Infectious Disease. Indication: Unspecified Influenza Virus Infections
Therapy area: Oncology. Indication: Lung Adenocarcinoma, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Solid Tumor, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Uterine Cancer
Therapy area: Hematological Disorders, Immunology. Indication: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Thrombocytopenia
Therapy area: Cardiovascular. Indication: Hypertension
Therapy area: Central Nervous System. Indication: Post-Operative Pain
Therapy area: Oncology. Indication: Advanced Malignancy, Diffuse Large B-Cell Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Solid Tumor
Therapy area: Undisclosed. Indication: Unspecified
Therapy area: Immunology. Indication: Unspecified Immunological Disorders
Therapy area: Gastrointestinal, Immunology. Indication: Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Ulcerative Colitis
Therapy area: Hematological Disorders. Indication: Iron Deficiency Anemia
Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)
Therapy area: Gastrointestinal, Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma), Hepatocellular Carcinoma, Liver Cancer, Liver Cirrhosis, Metastatic Liver Cancer
Therapy area: Central Nervous System. Indication: Unspecified Pain
Therapy area: Cardiovascular. Indication: Hypertension
Therapy area: Infectious Disease. Indication: Hepatitis B